Skip to main content

Table 1 Patients’ demographic, clinical and lifestyle characteristics collected at T0 assessment: the whole cohort and those who completed follow-up at T3

From: Weight and waist-to-hip ratio change pattern during the first five years of survival: data from a longitudinal observational Chinese breast cancer cohort

Characteristics The whole cohort(n = 1462), n (%) who completed follow-up at T3, (n = 1117), n (%)
Time from diagnosis to T0 assessment, median (range), months 3.2 (0.1–11.9) 3.2 (0.1–11.9)
Age at diagnosis, mean (SD), years 51.9 (9.1) 51.9 (8.8)
Age group at diagnosis, years
 < 40 150 (10.3) 111 (9.5)
 40–49 468 (32.0) 383 (32.7)
 50–59 552 (37.7) 444 (37.9)
 ≥60 292 (20.0) 233 (19.9)
Education level
 High school or below 1230 (84.1) 987 (84.3)
 College or above 232 (15.9) 184 (15.7)
Marital status
 Married or cohabitation 1039 (71.1) 840 (71.7)
 Unmarried or divorced or widowed 423 (28.9) 331 (28.3)
Family income, HKD/month
 < 15,000 683 (46.7) 530 (45.3)
 15,000-30,000 452 (30.9) 375 (32.0)
 30,000-50,000 204 (14.0) 174 (14.9)
 ≥50,000 123 (8.4) 92 (7.9)
Employment status
 Full time 545 (37.3) 433 (37.0)
 Part time 195 (13.3) 146 (12.5)
 Not working 722 (49.4) 592 (50.6)
Number of comorbidities
 0 901 (61.6) 726 (62.0)
 1 371 (25.4) 296 (25.3)
 ≥2 190 (13.0) 149 (12.7)
Menopausal status at T0 assessment
 Pre-menopausal 782 (53.5) 627 (53.5)
 Post-menopausal 680 (46.5) 544 (46.5)
Parity
 0 339 (23.2) 281 (24.0)
 1 340 (23.3) 260 (22.2)
 2 531 (36.3) 429 (36.6)
 ≥3 252 (17.2) 201 (17.2)
AJCC stage
 0-I 523 (35.8) 438 (37.4)
 II 652 (44.6) 529 (45.2)
 III 276 (18.9) 197 (16.8)
 Missing 11 (0.8) 7 (0.6)
Histology
 IDC 1225 (83.8) 982 (83.8)
 ILC 42 (2.9) 35 (3.0)
 DCIS 94 (6.3) 70 (6.0)
 Others 101 (6.9) 84 (7.2)
ER status, %
 Positive 1057 (72.3) 870 (74.3)
 Negative 363 (24.8) 272 (23.2)
 Missing 42 (2.9) 29 (2.5)
PR status, %
 Positive 810 (55.4) 675 (57.6)
 Negative 605 (41.4) 463 (39.5)
 Missing 47 (3.2) 33 (2.8)
HER 2 status, %
 Positive 381 (26.1) 305 (26.0)
 Negative 966 (66.1) 786 (67.1)
 Missing 115 (7.9) 80 (6.8)
Type of surgery
 Mastectomy 917 (62.7) 714 (61.0)
Conservation 545 (37.3) 457 (39.0)
 Chemotherapy, %
 Yes 1100 (75.2) 875 (74.7)
 No 362 (24.8) 296 (25.3)
Radiotherapy, %
 Yes 1032 (70.6) 825 (70.5)
 No 430 (29.4) 346 (29.5)
Endocrine therapy, %
 Yes 1054 (72.1) 875 (74.7)
 No 408 (27.9) 296 (25.2)
Height, median (range), cm 156 (137–177) 156 (137–177)
Weight, median (range), kg 56.0 (33.4–111.0) 55.4 (34.3–110.0)
BMI at diagnosis, kg/m2
 Underweight (< 18.5) 53 (3.6) 51 (4.4)
 Normal (18.5–22.9) 713 (48.8) 540 (46.1)
 Overweight (23–24.9) 297 (20.3) 251 (21.4)
 Obese (≥25) 399 (27.3) 329 (28.1)
 Waist circumference, median (range), cm 80.3 (58.5–126.5) 80.2 (58.5–126.5)
 Hip circumference, median (range), cm 95.0 (78.0–136.5) 95.0 (78.0–135.0)
WHR at T0 assessment
 < 0.85 762 (52.1) 607 (51.8)
 ≥0.85 701 (47.9) 564 (48.2)
Sports participation 1-year before diagnosis
 Never 666 (45.6) 530 (45.3)
 Rarely/occasionally 487 (33.1) 399 (34.1)
 Frequently 309 (21.1) 242 (20.7)
Dietary energy intake 1-year before diagnosis, median (range), kcal/day 1620.3 (551.1–5787.3) 1616.6 (551.1–5787.3)
Dietary carbohydrate intake1-year before diagnosis, median (range), kcal/day 121.2 (56.9–191.2) 121.3 (56.9–191.2)
Dietary fat intake 1-year before diagnosis, median (range), g/1000 kcal/day 39.1 (14.2–62.7) 39.0 (14.2–62.7)
Coffee intake 1-year before diagnosis, ml/week
 < 200 991 (67.8) 785 (67.0)
 ≥200 471 (32.2) 386 (33.0)
Sugar-sweetened beverage intake1-year before diagnosis, ml/week
 < 200 1178 (80.6) 952 (81.3)
 ≥200 284 (19.4) 219 (18.7)
Vegetables and fruits intake 1-year before diagnosis, g/day
 < 400 496 (33.9) 399 (34.1)
 ≥400 966 (66.1) 772 (65.9)
Ever smoking before diagnosis
 Yes 22 (1.5) 21 (1.8)
 No 1440 (98.5) 1150 (98.2)
Ever frequent alcohol intake before diagnosis (>  4 times/week)
 Yes 28 (1.9) 16 (1.4)
 No 1434 (98.1) 1155 (98.6)
  1. Abbreviations: SD standard deviation; HKD Hong Kong dollars; BMI body mass index; AJCC American joint Committee on cancer; IDC invasive ductal carcinoma; ILC invasive lobular carcinoma; DCIS ductal carcinoma in situ; ER estrogen receptor; PR progesterone receptor; HER 2 human epidermal-growth-factor receptor 2; MET metabolic equivalent of task; g gram